This invention pertains to compounds which specifically inhibit the
adenosine A.sub.1 and A.sub.3 receptors and the use of these compounds to
treat a disease associated with A3 adenosine receptor in a subject,
comprising administering to the subject a therapeutically effective
amount of the compounds.